Led · Equity · Jun 2026

CameraMatics has built a connected fleet-intelligence platform that combines AI-driven video intelligence, advanced driver assistance systems (ADAS) and real-time operational analytics to improve driver safety, reduce operational risk and lower carbon emissions. The company reports consistent strong revenue growth, serving nearly 1,000 fleet customers and supporting operations across thousands of commercial vehicles. CameraMatics employs more than 150 people across offices in Dublin, Waterford, Darlington, London, Amsterdam, Barcelona and the United States. Recent contract wins include customers such as Royal Mail, Calor Gas, Wolseley, XPO and DFDS, and in the US it has expanded through deployments with Installed Building Products. The company states it continues to invest heavily in innovation, machine learning, predictive safety technologies and connected fleet intelligence, and aims to scale enterprise adoption across North America and mainland Europe.

Participated · Series B · Apr 2026

Manna Air Delivery operates a regulated consumer drone delivery network using proprietary software and hardware to deliver everyday items in minutes to suburban customers. The company has completed more than 250,000 regulated commercial UAV flights, holds a Gold Standard Light UAS Operator Certificate under EASA, and employs over 170 staff. Manna reports deliveries in under three minutes, an NPS of 86, and claims CO2 emissions reductions of up to 85% versus road-based delivery. It currently operates in Ireland, Finland and Texas and has partnerships with platforms including Uber, Deliveroo, Just Eat and DoorDash. Founded in 2019, Manna positions itself as an infrastructure provider for instant logistics and plans to scale to as many as 40 bases in the United States with the new funding.

Led · Equity · Jan 2026

Equal1 positions itself as a “quantum semiconductor company,” building quantum processors on conventional CMOS processes so they can be fabricated in existing foundries and deployed without dilution refrigerators or specialized facilities. Its flagship product, Bell-1, is a rack-mounted quantum server designed to slide into standard data-center infrastructure and is already shipping to customers, including an installation planned for the European Space Agency’s Space HPC Center in Italy. The company’s UnityQ processor family follows a quantum-system-on-chip approach that integrates quantum and classical components on a single piece of silicon to cut cost, size, and complexity. Equal1 argues that this architecture will help alleviate power and cost constraints facing classical computing as AI workloads grow. Proceeds from the latest financing will fund broader deployments across high-performance computing centers, increase on-chip qubit counts, scale manufacturing through foundry partners, and expand headcount. Including the new raise, Equal1 has secured more than $85 million in total funding to date.

Participated · Series B · Aug 2025

ProVerum Ltd. is a Dublin-based developer of the ProVee® System, an investigational, minimally invasive treatment for BPH. The ProVee System uses a nitinol stent designed to gently re-shape the enlarged prostate and alleviate lower urinary tract symptoms, and is delivered through a low-profile, flexible, steerable delivery system with integrated imaging. The device is investigational and, per the company, is limited by law to investigational use and not available for sale within the United States. ProVerum says proceeds from the financing will be used to prepare for commercialization. The company has emphasized preparing to commercialize its novel treatment for men with BPH as it advances development. Leadership changes accompanying the financing include additions to the board from investor partners.

Participated · Equity · Jan 2025

FIRE1 is a connected medical device solutions company headquartered in Dublin, Ireland, developing the Norm™ heart failure management system. Norm™ enables physician-directed self-management by measuring fluid volume more directly and providing patients with actionable data to manage heart failure. The system is designed to reduce burdens on healthcare staff, keep patients healthier at home, and prevent frequent hospitalizations. FIRE1 completed a $120 million financing to accelerate development and will use the funds to complete a pivotal clinical trial of the Norm™ system. The company has received FDA Breakthrough Device Designation and was accepted into the FDA’s Total Product Lifecycle Advisory Program (TAP). FIRE1 collaborates with researchers, clinicians, patients, and payors and announced board additions tied to the financing. FIRE1 is a connected medical device solutions company developing a remote monitoring solution intended to improve outcomes for people with heart failure. Headquartered in Dublin, Ireland, the company says its mission is to help millions of heart failure patients regain their normal lives. The team works closely with world-leading researchers, clinicians, patients and payors to reduce the burden of chronic disease. FIRE1 recently closed an oversubscribed $25 million financing to accelerate development of its novel home monitoring solution. Management positions the product as a way to reduce hospitalizations and improve care for the large heart-failure population. FIRE1 develops a novel remote monitoring solution aimed at improving outcomes for people with heart failure. The company is led by an experienced medical devices team and works closely with researchers, clinicians, patients and payors. The financing announced will provide capital to further advance its heart-failure remote monitoring product and accelerate development. FIRE1 positions its solution as a means to manage patients at home and reduce hospitalizations and associated costs. The company is headquartered in Dublin and is the 15th medical device company from The Foundry. Management emphasizes collaboration with leading clinicians to support adoption and clinical validation. FIRE1 develops a novel remote monitoring device for medical applications. The Dublin-based company raised $7.5m in a Series B financing. Leadership includes Conor Hanley (President and CEO), John Britton (VP of Commercial Operations), and Fiachra Sweeney (Senior Director of Engineering). In conjunction with the round, The Foundry's Managing Director Mark Deem was appointed Chairman of the Board. FIRE1 is the 15th medical-device company formed by The Foundry, a Menlo Park, California incubator founded in 1998 that creates new medical device companies and works with outside clinicians and inventors. The Foundry has formed over fifteen companies, including Ardian, Concentric Medical, Evalve and Twelve, several of which were later acquired by major medical firms. FIRE1 was launched by The Foundry to develop novel therapeutic devices and is based in Dublin, Ireland. The company plans to use its Series A funding to develop and commercialize solutions addressing certain unmet medical needs. Specific market plans and financing terms were not disclosed in the announcement. The Foundry expanded FIRE1's board to include representatives from investors and partners, and Mark Deem is serving as chief executive. FIRE1 is described as The Foundry's first company created in Ireland and benefits from collaboration with strategic partners in the medical device industry. The announcement frames the partnership as aligning with Covidien's strategy to bring clinically relevant and cost-effective new treatment options to market.